Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 1
2016 5
2017 5
2018 5
2019 8
2020 13
2021 13
2022 6
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Vessel size as a marker of survival in estrogen receptor positive breast cancer.
Milosevic V, Edelmann RJ, Winge I, Strell C, Mezheyeuski A, Knutsvik G, Askeland C, Wik E, Akslen LA, Östman A. Milosevic V, et al. Among authors: mezheyeuski a. Breast Cancer Res Treat. 2023 Jul;200(2):293-304. doi: 10.1007/s10549-023-06974-4. Epub 2023 May 24. Breast Cancer Res Treat. 2023. PMID: 37222874 Free PMC article.
Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer.
Backman M, Strell C, Lindberg A, Mattsson JSM, Elfving H, Brunnström H, O'Reilly A, Bosic M, Gulyas M, Isaksson J, Botling J, Kärre K, Jirström K, Lamberg K, Pontén F, Leandersson K, Mezheyeuski A, Micke P. Backman M, et al. Among authors: mezheyeuski a. Eur J Cancer. 2023 May;185:40-52. doi: 10.1016/j.ejca.2023.02.012. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 36963351 Free article.
An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers.
Mezheyeuski A, Backman M, Mattsson J, Martín-Bernabé A, Larsson C, Hrynchyk I, Hammarström K, Ström S, Ekström J, Mauchanski S, Khelashvili S, Lindberg A, Agnarsdóttir M, Edqvist PH, Huvila J, Segersten U, Malmström PU, Botling J, Nodin B, Hedner C, Borg D, Brändstedt J, Sartor H, Leandersson K, Glimelius B, Portyanko A, Ponten F, Jirström K, Micke P, Sjöblom T. Mezheyeuski A, et al. EBioMedicine. 2023 Feb;88:104452. doi: 10.1016/j.ebiom.2023.104452. Epub 2023 Jan 30. EBioMedicine. 2023. PMID: 36724681 Free PMC article.
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G. Ellingsen EB, et al. Among authors: mezheyeuski a. J Transl Med. 2022 Sep 11;20(1):419. doi: 10.1186/s12967-022-03624-z. J Transl Med. 2022. PMID: 36089578 Free PMC article. Clinical Trial.
Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features.
Pellinen T, Paavolainen L, Martín-Bernabé A, Papatella Araujo R, Strell C, Mezheyeuski A, Backman M, La Fleur L, Brück O, Sjölund J, Holmberg E, Välimäki K, Brunnström H, Botling J, Moreno-Ruiz P, Kallioniemi O, Micke P, Östman A. Pellinen T, et al. Among authors: mezheyeuski a. J Natl Cancer Inst. 2023 Jan 10;115(1):71-82. doi: 10.1093/jnci/djac178. J Natl Cancer Inst. 2023. PMID: 36083003
60 results